RecruitingNot applicableNCT02402244
Project: Every Child for Younger Patients With Cancer
Studying Hereditary pheochromocytoma-paraganglioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Douglas S HawkinsChildren's Oncology Group
- Intervention
- Cytology Specimen Collection Procedure(other)
- Enrollment
- 75000 enrolled
- Eligibility
- 25 years · All sexes
- Timeline
- 2015 – 2030
Study locations (20)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- USA Health Strada Patient Care Center, Mobile, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Banner Children's at Desert, Mesa, Arizona, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Mattel Children's Hospital UCLA, Los Angeles, California, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02402244 on ClinicalTrials.govOther trials for Hereditary pheochromocytoma-paraganglioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06479811[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersNational Cancer Institute (NCI)
- RECRUITINGNANCT06377033Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemUniversity of Pennsylvania
- RECRUITINGNCT06444607Hereditary Pheochromocytoma Assessment of Tumour ImmunologiesRadboud University Medical Center
- RECRUITINGPHASE4NCT05702944The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive PheochromocytomaSeoul National University Hospital
- ACTIVE NOT RECRUITINGNCT05233878Prognostic's Factors of Head and Neck Paragangliomas EvolutionHospices Civils de Lyon
- ACTIVE NOT RECRUITINGPHASE2NCT05142241Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialNational Cancer Institute (NCI)
- RECRUITINGNANCT03344016Multicenter Pheochromocytoma and Paraganglioma EvaluationFelix Beuschlein
- RECRUITINGNCT03160274Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated ConditionsThe University of Texas Health Science Center at San Antonio
See all trials for Hereditary pheochromocytoma-paraganglioma →